BRPI0902481B8 - composição farmacêutica compreendendo hemopressina e seu uso. - Google Patents
composição farmacêutica compreendendo hemopressina e seu uso.Info
- Publication number
- BRPI0902481B8 BRPI0902481B8 BRPI0902481A BRPI0902481A BRPI0902481B8 BR PI0902481 B8 BRPI0902481 B8 BR PI0902481B8 BR PI0902481 A BRPI0902481 A BR PI0902481A BR PI0902481 A BRPI0902481 A BR PI0902481A BR PI0902481 B8 BRPI0902481 B8 BR PI0902481B8
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- treatment
- relates
- present
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- DUTLYPZZJJBEAJ-QISMNGAHSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-3-methyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H]1NCCC1)C(C)C)C1=CC=CC=C1 DUTLYPZZJJBEAJ-QISMNGAHSA-N 0.000 title 1
- 108010000680 hemopressin Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 6
- 206010061218 Inflammation Diseases 0.000 abstract 3
- 230000004054 inflammatory process Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 208000030814 Eating disease Diseases 0.000 abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 2
- 208000004454 Hyperalgesia Diseases 0.000 abstract 2
- 208000035154 Hyperesthesia Diseases 0.000 abstract 2
- 235000014632 disordered eating Nutrition 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composição farmacêutica, método para tratamento de inflamação, método para tratamento de hiperalgesia e método para tratamento de distúrbio alimentar. a presente invenção refere-se a uma composição farmacêutica que compreende um ingrediente ativo endógeno, como um peptídeo, que atua como antagonista e/ ou agonista inverso para o tratamento de uma condição médica, particularmente uma condição médica acompanhada de dor e/ ou inflamação, de maneira preventiva e/ ou combativa. a presente invenção também refere-se a um método para tratar inflamações que compreende a administração de tal composição em um indivíduo que necessita de tal tratamento. a presente invenção também refere-se a um método para tratar hiperalgesia que compreende a administração de tal composição em um individuo que necessita de tal tratamento. a presente invenção também refere-se a um método para tratar distúrbios alimentares, especialmente a obesidade, que compreende a administração de tal composição em um individuo que necessita de tal tratamento.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0902481A BRPI0902481B8 (pt) | 2009-07-31 | 2009-07-31 | composição farmacêutica compreendendo hemopressina e seu uso. |
| ES10742073.9T ES2447823T3 (es) | 2009-07-31 | 2010-07-30 | Composición farmacéutica para su utilización en el tratamiento de la obesidad, diabetes o para aumentar la sensibilidad a la insulina |
| PCT/BR2010/000253 WO2011011847A2 (en) | 2009-07-31 | 2010-07-30 | Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases |
| PT107420739T PT2459207E (pt) | 2009-07-31 | 2010-07-30 | Composição farmacêutica para tratamento de condições médicas e um método para tratamento de distúrbios alimentares e doenças relacionadas |
| US13/388,194 US20130196904A1 (en) | 2009-07-31 | 2010-07-30 | Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases |
| EP10742073.9A EP2459207B1 (en) | 2009-07-31 | 2010-07-30 | Pharmaceutical composition for use in treating obesity, diabetes or to increase insulin sensitivity |
| US14/703,466 US9452196B2 (en) | 2009-07-31 | 2015-05-04 | Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0902481A BRPI0902481B8 (pt) | 2009-07-31 | 2009-07-31 | composição farmacêutica compreendendo hemopressina e seu uso. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0902481A2 BRPI0902481A2 (pt) | 2011-04-05 |
| BRPI0902481B1 BRPI0902481B1 (pt) | 2020-02-04 |
| BRPI0902481B8 true BRPI0902481B8 (pt) | 2021-05-25 |
Family
ID=43333134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0902481A BRPI0902481B8 (pt) | 2009-07-31 | 2009-07-31 | composição farmacêutica compreendendo hemopressina e seu uso. |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130196904A1 (pt) |
| EP (1) | EP2459207B1 (pt) |
| BR (1) | BRPI0902481B8 (pt) |
| ES (1) | ES2447823T3 (pt) |
| PT (1) | PT2459207E (pt) |
| WO (1) | WO2011011847A2 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201113596D0 (en) | 2011-08-08 | 2011-09-21 | Univ De Coimbra | Compounds, compositions and methods to promote oligodendrogenesis and remyelination |
| BR102012017421A2 (pt) | 2012-07-13 | 2015-04-14 | Proteimax Biotecnolgia Ltda | Peptídeo, composicão farmacêutica, ligante de receptor cb, metodo para modular a funcao de receptor cb, uso, método para o tratamento de obesidade, e, método para promover a redução de peso estetica em um indivíduo |
| DK2878306T3 (en) * | 2012-07-13 | 2019-03-04 | Proteimax Biotecnologia Ltda | MODIFIED PEPTIDE, CB RECEPTOR LIGAND, KIT, IN VITRO PROCEDURE FOR EVALUATION OF CB RECEPTOR BINDINGS, APPLICATIONS, PHARMACEUTICAL COMPOSITION FOR MODULATING CBRECEPTOR ACTIVITY |
| RU2537171C2 (ru) * | 2013-03-04 | 2014-12-27 | Фармаплант Фабрикацион Хемишер Продукте ГмбХ | Биологически активный пептид и способы его применения |
| WO2018068120A1 (pt) * | 2016-10-13 | 2018-04-19 | Proteimax Biotecnologia Ltda | Uso de composto, intermediário de síntese, composição farmacêutica e método terapêutico neuromodulador |
| BR102017010169A2 (pt) | 2017-05-15 | 2019-02-26 | Remer Consultores Assessoria Empresarial Ltda. | composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante |
| BR102016023848A2 (pt) * | 2016-10-13 | 2018-05-02 | Proteimax Biotecnologia Ltda | Anticonvulsivante, uso e composição farmacêutica contendo o mesmo |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00673B (me) * | 2000-05-15 | 2011-12-20 | Hoffmann La Roche | Nova farmaceutska smjesa |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| WO2004034968A2 (en) | 2002-08-20 | 2004-04-29 | The Regents Of The University Of California | Combination therapy for controlling appetites |
| US20060100205A1 (en) | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
| US20060218413A1 (en) | 2005-03-22 | 2006-09-28 | International Business Machines Corporation | Method of introducing physical device security for digitally encoded data |
| EP1879582A4 (en) * | 2005-05-02 | 2009-05-13 | Merck & Co Inc | COMBINATION OF A DIPEPTIDYLPEPTIDASE IV HEMMER AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND ADIPOSITAS |
-
2009
- 2009-07-31 BR BRPI0902481A patent/BRPI0902481B8/pt active IP Right Grant
-
2010
- 2010-07-30 WO PCT/BR2010/000253 patent/WO2011011847A2/en not_active Ceased
- 2010-07-30 EP EP10742073.9A patent/EP2459207B1/en active Active
- 2010-07-30 US US13/388,194 patent/US20130196904A1/en not_active Abandoned
- 2010-07-30 PT PT107420739T patent/PT2459207E/pt unknown
- 2010-07-30 ES ES10742073.9T patent/ES2447823T3/es active Active
-
2015
- 2015-05-04 US US14/703,466 patent/US9452196B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150297669A1 (en) | 2015-10-22 |
| ES2447823T3 (es) | 2014-03-13 |
| BRPI0902481A2 (pt) | 2011-04-05 |
| WO2011011847A8 (en) | 2011-03-31 |
| US20130196904A1 (en) | 2013-08-01 |
| PT2459207E (pt) | 2014-02-21 |
| EP2459207A2 (en) | 2012-06-06 |
| WO2011011847A2 (en) | 2011-02-03 |
| WO2011011847A3 (en) | 2011-06-16 |
| EP2459207B1 (en) | 2013-11-20 |
| US9452196B2 (en) | 2016-09-27 |
| BRPI0902481B1 (pt) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022497A2 (pt) | Composto, composição farmacêutica, uso da composição farmacêutica, e, métodos para prevenir ou tratar obesidade, diabetes, inflamação e disfunção erétil | |
| BRPI0902481B8 (pt) | composição farmacêutica compreendendo hemopressina e seu uso. | |
| ECSP12011962A (es) | Tratamientos para trastornos gastrointestinales | |
| BR112012021905A2 (pt) | tratamento de nefrite lúpica usando laquinimod | |
| BR112012005044B8 (pt) | composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| WO2009021058A3 (en) | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy | |
| BR112014007532A2 (pt) | variantes do fator de crescimento de fibroblastos 21 | |
| MX2010009447A (es) | Uso de antagonistas de lhrh a dosis no castrantes. | |
| BRPI0917315B8 (pt) | anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| CR20110509A (es) | Composicion farmaceutica | |
| BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| TW201129378A (en) | Materials and methods for treating or preventing HER-3 associated diseases | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| BR112012022187A2 (pt) | tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato | |
| EA201270226A1 (ru) | Витамин d3 и его аналогии для лечения алопеции | |
| BR112012022064A2 (pt) | tratamento de artrite lúpica usando laquinimod | |
| MX2012006430A (es) | Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide. | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| MX346576B (es) | Metodos y composiciones adecuados para promover piel sana. | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| BR112012006010A2 (pt) | composto de glicina | |
| BR112016013754A2 (pt) | Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09Y | Publication of grant cancelled [chapter 9.1.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 9.1 NA RPI NO 2530 DE 02/07/2019 POR TER SIDO INDEVIDA. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |